Case No. O2016_017 | Hearing of 3 June 2019
The patent at stake is MundiPharma‘s EP 2 425 825 B9; see EPO Register and Swissreg.
What’s the point about pointer?
→ Read more ...
Fumarate and phosphate: Same same, but different?
Case No. O2017_023 | Decision of 3 May 2019
This case is about an alleged infringement of Gilead’s SPC C00915894; the basic patent is (see EPO Register and Swissreg).
The money behind the pharmaceuticals being litigated
The Njardarson Group of the University of Arizona has just published the 2018 edition of the poster ‘Top 200 Pharmaceutical Products by Retail Sales‘ (file size is about 8 Mb).
Hip Hip Hooray: Stemcup and Implantec litigating about the ANA.NOVA hybrid socket
Case No. O2016_012 | Hearing of 29 May 2019
The patent in suit is EP 1 411 869 B1; see Swissreg and EPO Register for further information.
The expert opinion of the judge-rapporteur is not the end of the line
Case No. S2018_007 | Decision of 2 May 2019
The patent at stake is EP 3 027 362 B1 which is jointly owned by C&E Fein GmbH and Robert Bosch GmbH; see the EPO Register and Swissreg for further information.
Premature database entry infringes SPC
Case No. S2019_006 | Decision of 1 May 2019
Case No. S2019_006 | Decision of 21 March 2019
The SPC in suit is ICOS’ C00740668/01, the basic patent of which is EP 740 668 B1; see EPO Register and Swissreg for further information.
The first thematically structured main hearing at the FPC: Role model or nonstarter?
Case No. O2016_016 | Hearing of 8 May 2019
The patent at stake is MundiPharma‘s EP 2 425 825 B9; see EPO Register and Swissreg.
The EPO assesses all aspects of entitlement to priority. Rightly so.
Proper assignment of the right to claim priority is intensely discussed in recent times, in particular the way how the EPO addresses such issues.
Should instruction hearings and/or court-mediated settlement talks be public?
The FPC has attempted from the very beginning to settle its cases by compromise; see e.g. the (p 6, left col):
The Federal Patent Court sees itself as a service provider to the private sector.
Fulvestrant, revisited: Is it still urgent? Views are divergent …
Case No. S2019_004 | Decision of 9 April 2019
Case No. S2019_004 | Decision of 20 February 2019
With request of 12 February 2019, AstraZeneca asserted EP(CH) 2 266 573 B1 (see EPO Register and Swissreg for further information) against Sandoz’s generic version of AZ’s Faslodex®, i.e.
Anything but a quick fix: Coram beavering away at knocking out a patent
Case No. S2018_007 | Hearing of 15 April 2019
The patent at stake is EP 3 027 362 B1 which is jointly owned by C&E Fein GmbH and Robert Bosch GmbH; see the EPO Register and Swissreg for further information.
Generic Kivexa®: Supreme Court confirms interim injunctive relief
Case No. 4A_575/2018 (Supreme Court) | Decision of 12 March 2019 on appeal against S2018_004 (FPC) | Decision of 22 October 2018 | ‘Abacavir / Lamivudine’
Please see this Blog here for a detailed review of the first instance decision S2018_004 of the FPC in this matter, granting interim injunctive relief against Sandoz’s generic Kivexa®.